Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Journal Article (Journal Article)

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Full Text

Duke Authors

Cited Authors

  • Go, RS; Jacobsen, E; Baiocchi, R; Buhtoiarov, I; Butler, EB; Campbell, PK; Coulter, DW; Diamond, E; Flagg, A; Goodman, AM; Goyal, G; Gratzinger, D; Hendrie, PC; Higman, M; Hogarty, MD; Janku, F; Karmali, R; Morgan, D; Raldow, AC; Stefanovic, A; Tantravahi, SK; Walkovich, K; Zhang, L; Bergman, MA; Darlow, SD

Published Date

  • November 2021

Published In

Volume / Issue

  • 19 / 11

Start / End Page

  • 1277 - 1303

PubMed ID

  • 34781268

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2021.0053


  • eng

Conference Location

  • United States